Current Heart Failure Reports

, Volume 6, Issue 4, pp 236–244 | Cite as

Who should receive an implantable cardioverter-defibrillator after myocardial infarction?

Article

Abstract

Despite a decline in overall cardiovascular mortality, the incidence of sudden cardiac death (SCD) continues to rise. Patients who survive a myocardial infarction (MI) with depressed ejection fraction are at particularly high risk for SCD. The development of implantable cardioverter-defibrillators (ICDs) has revolutionized SCD prevention; however, despite the current fervor for device implantation, many unresolved questions remain about risk stratification in post-MI patients. This review presents the current indications and timing of ICD implantation for primary and secondary prevention of SCD after MI. Several conventional and investigational methods of risk stratification after MI, as well as current controversies regarding device implantation in specific patient populations, are also reviewed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Myerburg RJ, Kessler KM, Castellanos A: Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993, 119:1187–1197.PubMedGoogle Scholar
  2. 2.
    de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al.: Out-of-hospital cardiac arrest in the 1990s: a populationbased study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997, 30:1500–1505.CrossRefPubMedGoogle Scholar
  3. 3.
    Solomon SD, Zelenkofske S, McMurray JJ, et al.: Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005, 352:2581–2588.CrossRefPubMedGoogle Scholar
  4. 4.
    A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The antiarrhythmics versus implantable defibrillators (AVID) investigators. N Engl J Med 1997, 337:1576–1583.Google Scholar
  5. 5.
    Kuck KH, Cappato R, Siebels J, et al.: Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000, 102:748–754.PubMedGoogle Scholar
  6. 6.
    Connolly SJ, Gent M, Roberts RS, et al.: Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000, 101:1297–1302.PubMedGoogle Scholar
  7. 7.
    Connolly SJ, Hallstrom AP, Cappato R, et al.: Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator Study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000, 21:2071–2078.CrossRefPubMedGoogle Scholar
  8. 8.
    Raitt MH, Renfroe EG, Epstein AE, et al.: “Stable” ventricular tachycardia is not a benign rhythm: insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. Circulation 2001, 103:244–252.PubMedGoogle Scholar
  9. 9.
    Bigger JT Jr, Fleiss JL, Kleiger R, et al.: The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984, 69:250–258.PubMedGoogle Scholar
  10. 10.
    Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788.PubMedGoogle Scholar
  11. 11.
    Waldo AL, Camm AJ, deRuyter H, et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival With Oral d-Sotalol. Lancet 1996, 348:7–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993, 270:1589–1595.CrossRefPubMedGoogle Scholar
  13. 13.
    Cairns JA, Connolly SJ, Roberts R, et al.: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997, 349:675–682.CrossRefPubMedGoogle Scholar
  14. 14.
    Moss AJ, Hall WJ, Cannom DS, et al.: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 1996, 335:1933–1940.CrossRefPubMedGoogle Scholar
  15. 15.
    Buxton AE, Lee KL, Fisher JD, et al.: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 1999, 341:1882–1890.CrossRefPubMedGoogle Scholar
  16. 16.
    Moss AJ, Zareba W, Hall WJ, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877–883.CrossRefPubMedGoogle Scholar
  17. 17.
    Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225–237.CrossRefPubMedGoogle Scholar
  18. 18.
    Bristow MR, Saxon LA, Boehmer J, et al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140–2150.CrossRefPubMedGoogle Scholar
  19. 19.
    Kadish A, Dyer A, Daubert JP, et al.: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350:2151–2158.CrossRefPubMedGoogle Scholar
  20. 20.
    Sanders GD, Hlatky MA, Owens DK: Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005, 353:1471–1480.CrossRefPubMedGoogle Scholar
  21. 21.
    Stecker EC, Vickers C, Waltz J, et al.: Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon sudden unexpected death study. J Am Coll Cardiol 2006, 47:1161–1166.CrossRefPubMedGoogle Scholar
  22. 22.
    Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al.: Out-of-hospital cardiac arrest—the relevance of heart failure. The Maastricht circulatory arrest registry. Eur Heart J 2003, 24:1204–1209.CrossRefPubMedGoogle Scholar
  23. 23.
    Buxton AE, Lee KL, Hafley GE, et al.: Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 2007, 50:1150–1157.CrossRefPubMedGoogle Scholar
  24. 24.
    Gehi AK, Stein RH, Metz LD, et al.: Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol 2005, 46:75–82.CrossRefPubMedGoogle Scholar
  25. 25.
    Chow T, Kereiakes DJ, Bartone C, et al.: Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 2007, 49:50–58.CrossRefPubMedGoogle Scholar
  26. 26.
    Costantini O, Hohnloser SH, Kirk MM, et al.: The ABCD (Alternans Before Cardioverter Defibrillator) trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol 2009, 53:471–479.CrossRefPubMedGoogle Scholar
  27. 27.
    Cantillon DJ, Stein KM, Markowitz SM, et al.: Predictive value of microvolt T-wave alternans in patients with left ventricular dysfunction. J Am Coll Cardiol 2007, 50:166–173.CrossRefPubMedGoogle Scholar
  28. 28.
    Gold MR, Ip JH, Costantini O, et al.: Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation 2008, 118:2022–2028.CrossRefPubMedGoogle Scholar
  29. 29.
    Statters DJ, Malik M, Ward DE, et al.: QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994, 5:672–685.CrossRefPubMedGoogle Scholar
  30. 30.
    Bailey JJ, Berson AS, Handelsman H, et al.: Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001, 38:1902–1911.CrossRefPubMedGoogle Scholar
  31. 31.
    Bauer A, Guzik P, Barthel P, et al.: Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfusion era. Eur Heart J 2005, 26:755–761.CrossRefPubMedGoogle Scholar
  32. 32.
    Bauer A, Watanabe MA, Barthel P, et al.: QRS duration and late mortality in unselected post-infarction patients of the revascularization era. Eur Heart J 2006, 27:427–433.CrossRefPubMedGoogle Scholar
  33. 33.
    Buxton AE, Sweeney MO, Wathen MS, et al.: QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. J Am Coll Cardiol 2005, 46:310–316.CrossRefPubMedGoogle Scholar
  34. 34.
    La Rovere MT, Bigger JT Jr, Marcus FI, et al.: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) investigators. Lancet 1998, 351:478–484.CrossRefPubMedGoogle Scholar
  35. 35.
    Schmidt A, Azevedo CF, Cheng A, et al.: Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 2007, 115:2006–2014.CrossRefPubMedGoogle Scholar
  36. 36.
    Verberne HJ, Brewster LM, Somsen GA, et al.: Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008, 29:1147–1159.CrossRefPubMedGoogle Scholar
  37. 37.
    Tamaki S, Yamada T, Okuyama Y, et al.: Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009, 53:426–435.CrossRefPubMedGoogle Scholar
  38. 38.
    Bello D, Fieno DS, Kim RJ, et al.: Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005, 45:1104–1108.CrossRefPubMedGoogle Scholar
  39. 39.
    Kadish AH, Bello D, Finn JP, et al.: Rationale and design for the defibrillators to reduce risk by magnetic resonance imaging evaluation (DETERMINE) trial. J Cardiovasc Electrophysiol 2009 Jun 1 (Epub ahead of print).Google Scholar
  40. 40.
    Buxton AE, Lee KL, DiCarlo L, et al.: Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter unsustained tachycardia trial investigators. N Engl J Med 2000, 342:1937–1945.CrossRefPubMedGoogle Scholar
  41. 41.
    Daubert JP, Zareba W, Hall WJ, et al.: Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in multicenter automatic defibrillator implantation trial (MADIT) II patients. J Am Coll Cardiol 2006, 47:98–107.CrossRefPubMedGoogle Scholar
  42. 42.
    Hohnloser SH, Kuck KH, Dorian P, et al.: Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004, 351:2481–2488.CrossRefPubMedGoogle Scholar
  43. 43.
    Wilber DJ, Zareba W, Hall WJ, et al.: Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004, 109:1082–1084.CrossRefPubMedGoogle Scholar
  44. 44.
    Holmes DR Jr, Davis K, Gersh BJ, et al.: Risk factor profiles of patients with sudden cardiac death and death from other cardiac causes: a report from the coronary artery surgery study (CASS). J Am Coll Cardiol 1989, 13:524–530.PubMedCrossRefGoogle Scholar
  45. 45.
    Bigger JT Jr: Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) patch trial investigators. N Engl J Med 1997, 337:1569–1575.CrossRefPubMedGoogle Scholar
  46. 46.
    Bigger JT Jr, Whang W, Rottman JN, et al.: Mechanisms of death in the CABG patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999, 99:1416–1421.PubMedGoogle Scholar
  47. 47.
    Goldenberg I, Vyas AK, Hall WJ, et al.: Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008, 51:288–296.CrossRefPubMedGoogle Scholar
  48. 48.
    Epstein AE, Kay GN, Plumb VJ, et al.: Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm 2009 Apr 10 (Epub ahead of print).Google Scholar
  49. 49.
    Huang DT, Sesselberg HW, McNitt S, et al.: Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 2007, 18:833–838.CrossRefPubMedGoogle Scholar
  50. 50.
    Wase A, Basit A, Nazir R, et al.: Impact of chronic kidney disease upon survival among implantable cardioverterdefibrillator recipients. J Interv Card Electrophysiol 2004, 11:199–204.CrossRefPubMedGoogle Scholar
  51. 51.
    Sandner SE, Wieselthaler G, Zuckermann A, et al.: Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation 2001, 104:I171–I176.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Medicine, Cardiovascular DivisionUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations